Takeaway 

When used as a first-line adjunct to standard platinum-based chemotherapy, the anti-PD-1 antibody pembrolizumab provides a 40% increase in OS in women with advanced cervical cancer compared with chemotherapy alone, according to the final analysis data of the KEYNOTE-826 study, which will be presented during the annual meeting of ...